Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels

REFERENCES

• The D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735.
   PubMed Web of Science ®Google Scholar
• Sabin C, Worm S, Weber R, Reiss P, El-Sadr W, Thiebaut R, et al. Recent use of abacavir and didanosine, but not thymidine analogues, is associated with risk of myocardial infarction. In: Program and abstracts of the 15th Confer-ence on Retroviruses and Opportunistic Infections (CR01); February 2008; Boston, MA. Abstract 957c.
   Google Scholar
• Bozzette S, Ake C, Tam H, Phippard A, Cohen D, Scharfstein D, Louis T. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. JAIDS. 2008;47(3): 338–341.
   Google Scholar
• Hammer S, Eron J, Reiss P, Schooley R, Thompson M, Walmsley S, et al. Antiretroviral treatment of Adult HIV infection. 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300(5):555–570.
   PubMed Web of Science ®Google Scholar
• Law M, Früs-Moller N, El-Sadr W, Weber R, Reiss P, Arminio-Monforte A, et al. The use of the Framingham equation to predict myocardial infarction in HIV-infected patients: Comparison with observed events in the D.A.D study. HIV Med. 2006;7:218–230.
   PubMed Web of Science ®Google Scholar
• Anderson K, Odell P, Wilson P, Kennel W. Cardiovascular risk profiles. Am Heart J. 1990;121:293–298.
   Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow up of the Prospective Cardiovas-cular Munster (PROCAM) Study. Circulation. 2002;105: 310–315.
   PubMed Web of Science ®Google Scholar
• Blick G, Greiger-Zanlugo P, Plasencia V, Ulrich G, Heiman M, Alaie D, et al. STRESS: A study of cardiovascular risk evaluation by Framingham risk score and technetium Tc99 sestembi exercise stress testing (MIBI) comparing HIV-AIDS to non-HIV-infected patients. In: Program and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia. Abstract TUPEB062.
   Google Scholar
• Klein D, Hurley L, Silverberg M, Horberg M, Quesenberry C, Sidney S. Surveillance data for MI hospitalizations among HIV+ and HIV- Northern Californians. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (CR01); February 2007; Los Angeles, CA. Abstract 807.
   Google Scholar
• Malan N, Krantz E, Neal D, Kastango K, Frederick D, Mathew M. Efficacy and safety of atazanavir with and without ritonavir in antiretroviral-naive subjects. BMS089: 48-week results. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, CO. Abstract 107LB.
   Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002 ;346(26):2039–2046.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Ruxrungtham K, Slim J, Ward D, Larson P, Raffi F. The Gemini Study saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as ini-tial therapy in HIV-1 infected patients. In: Program and abstracts of the European AIDS Clinical Society Confer-ence; October 2007; Madrid, Spain. Abstract PS1/4.
   Google Scholar
• DeJesus E, Ortiz R, Khanlou H, Voronin E, vanLunzen J, Andrade-Villanueva J, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treat-ment naive HIV-1 infected patients at Week 48: ARTEMIS. In: Program and abstracts from ICAAC; September 2007; Chicago, IL. Abstract H–718b.
   Google Scholar
• Eron J, Yeni P, Gathe J, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavi-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, or initial treatment of HIV infec-tion over 48 weeks: A randomised non-inferiority trial. Lancet. 2006;368:476–482.
   PubMed Web of Science ®Google Scholar
• Gallant J, DeJesus E, Arribas J, Pozniak A, et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med. 2006;354:251–260.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292(2)191–201.
   Web of Science ®Google Scholar
• Martinez E, Arranz J, Podzdamczer D, Ribera E, Knobel H, Roca V, et al. Efficacy and safety of NRTI's switch to teno-fovir plus emtricitabine versus abacavir plus lamivudine in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study. In: Program and abstracts of the Fourth IAS Conference on HIV Patho-genesis, Treatment and Prevention; July 2007; Sydney, Australia. Abstract WESS101.
   Google Scholar
• van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. Vol. 1, No. 1, e19. doi:10.1371/ journal.pmed.0010019
   Web of Science ®Google Scholar
• Ruxrungtham K, Bellos N, Morales-Ramirez J, Timerman A, Madruga J, Katabira E, et al. The metabolic profile of TMC278, an investigational non-nucleoside reverse tran-scriptase inhibitor. In: Program and abstracts of the Fourth IAS Conference on HIV Pathogenesis, Treatment and Pre-vention; July 2007; Sydney, Australia. Abstract TUAB105.
   Google Scholar
• Haubrich R, et al. Metabolic outcomes of ACTG 5142: A prospective randomised phase III trial of NRTI, Pl- and NNRTI-sparing regimens for initial treatment of HIV-1 infec-tion. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles, CA. Abstract 38.
   Google Scholar
• Grundy S, Cleeman J, Bairey N, Merz A, Brewer H, Clark L. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239.
   PubMed Web of Science ®Google Scholar
• Bartlett J, Fath M, DeMasi R, Hermes A, Quinn J, Mondou E. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20(16):2051–2064.
   PubMed Web of Science ®Google Scholar
• Smith K, Weinberg W, DeJesus E, et al. Once-daily ritona-vir (100 mg) boosting of fosamprenavir or atazanavir with tenofovir /emticitabine in antiretroviral naïve HIV-infected patients: 48 week safety/efficacy results from COL103952 (ALERT). In: Program and abstracts of the Fourth IAS Con-ference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia. Abstract WEPEB023.
   Google Scholar
• Molina J, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Efficacy and safety of once-daily atazanavir-ritonavir compared to twice daily lopinavir-ritonavir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1 infected subjects: The CASTLE study, 48 week results. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (CR01); February 2008; Boston, MA. Abstract 37.
   Google Scholar
• Gathe J, Lye P, Wood R, Schurmann D, Bellos N, DeJesus E, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS. 2004; 18:1529–1537.
   PubMed Web of Science ®Google Scholar
• Johnson MA, Gathe JC, Podzamczer D, Molina J, Naylor C, Chiu Y, et al. A once-daily lopinavir/ritonavir based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006;43:153–160.
   PubMed Web of Science ®Google Scholar
• Gathe J, daSilva B, Loufty M, Podzdamczer D, Rubio R, Gibbs S, et al. Study M05-730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir-ritonavir (LPV/r) tablets once-daily (OD) versus twice-daily (BID), co-administered with tenofovir (TDF)+ emtricitabine (FTC) in antiretroviral naive (ARV) HIV-1 infected subjects. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (CR01); February 2008; Boston, MA. Abstract 775.
   Google Scholar
• Smith K, Fine D, Patel P, Bellos N, Sloan L, Lackey P, et al. Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtriticitabine in combination with one-daily lopinavir-ritonavir through 48 weeks in the HEAT Study. In: Program and abstracts of the 15th Conference on Retro-viruses and Opportunistic Infections (CR01); February 2008; Boston, MA. Abstract 774.
   Google Scholar
• Hicks C, De Jesus E, Wohl D, Liao Q, Pappa K, Lancaster T. Once-daily fosamprenavir boosted with either 100 mg or 200 mg of ritonavir along with abacavir/lamivudine: 48 week safety and efficacy results from COL100758. In: Program and abstracts of the 11th European AIDS Confer-ence; October 2007; Madrid, Spain. Abstract PS 7.01.
   Google Scholar
• Elion R, DeJesus E, Sension M, Berger D, Towner W, Richmond G, et al. Once-daily abacavir/lamivudine (ABC/3TC) and boosted atazanavir (ATV/RTV) in antiretro-viral-naive HIV-1 infected subjects: 48-week results from COL102060 (SHARE). Poster exhibition: 4th IAS Confer-ence on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia. Abstract WEPEB033.
   Google Scholar
• Cooper D, et al. Efficacy and safety of two doses of tipra-navir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naïve patients: Results of B11182.33. In: Pro-gram and abstracts of the Eighth International Congress on Drug Therapy in HIV Infection; 2006; Glasgow. Abstract PL13.4.
   Google Scholar
• Tomaka F, Lefebvre E, Sekar V, van Baelen B, Vangeneugden T, Vendervoorde A, et al. Similar changes in metabolic parameters of darunavir (TMC114) and atazana-vir, each coadmininstered with low-dose ritonavir in healthy volunteers. HIV DART: Frontiers in Drug Development of Antiretroviral Therapies; December 2006; Cancun, Mexico. Abstract 85.
   Google Scholar
• Vrouenraets S, Garcia E, Jackson A, Raffi F, Jayaweera D, Katlama C, et al. Saquinavir versus atazanavir once daily, each boosted with ritonavir 100 mg and combined with tenofovir/emtricitabine, result in comparable lipid changes after 24 weeks in treatment naïve HIV infected patients. Antiviral Ther 2008;13(Suppl 4):A46.
   Google Scholar
• Hense H. Observations, predictions and decisions — assessing cardiovascular risk assessment. Int J Epidemiol. 2004;33:235–239.
   PubMed Web of Science ®Google Scholar
• Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Zhao J, et al. Safety and efficacy of raltegravir-based versus efavirenz based combination therapy in treatment-naïve HIV-1 infected patients. In: Program and abstracts of the ICAAC-IDSA 2008 Conference; October 2008; Washington, DC. Abstract H896a.
   Google Scholar
• Kuller L, et al. Elevated levels of interleukin-6 and D-dimer are associated with an increased risk of death in patients with HIV. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, MA. Abstract 139.
   Google Scholar
• Calmy A, et al. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, MA. Abstract 140.
   Google Scholar